sorafenib has been researched along with rottlerin in 4 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (rottlerin) | Trials (rottlerin) | Recent Studies (post-2010) (rottlerin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 556 | 1 | 202 |
| Protein | Taxonomy | sorafenib (IC50) | rottlerin (IC50) |
|---|---|---|---|
| Eukaryotic elongation factor 2 kinase | Homo sapiens (human) | 5.3 | |
| B2 bradykinin receptor | Cavia porcellus (domestic guinea pig) | 1.2 | |
| Ubiquitin carboxyl-terminal hydrolase 1 | Homo sapiens (human) | 8 | |
| Beta-lactamase | Escherichia coli K-12 | 1.5 | |
| Malate dehydrogenase | Thermus thermophilus | 0.7 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.2 | |
| MAP kinase-activated protein kinase 2 | Homo sapiens (human) | 5.4 | |
| Protein kinase C delta type | Homo sapiens (human) | 3 | |
| MAP kinase-activated protein kinase 5 | Homo sapiens (human) | 1.9 | |
| WD repeat-containing protein 48 | Homo sapiens (human) | 8 | |
| RuvB-like 1 | Homo sapiens (human) | 10 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Jane, EP; Pollack, IF; Premkumar, DR | 1 |
| Kagechika, H; Kurosu, T; Miura, O; Ohki, M; Wu, N | 1 |
4 other study(ies) available for sorafenib and rottlerin
| Article | Year |
|---|---|
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
Topics: Acetophenones; Annexin A5; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Benzopyrans; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Proliferation; Cell Survival; Clone Cells; Drug Synergism; Enzyme Inhibitors; Glioma; Humans; Immunohistochemistry; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Folding; Protein Kinase C; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2006 |
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Topics: Acetophenones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfonates; Benzopyrans; Biphenyl Compounds; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Mutation; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2009 |